PEG & ADCs
- Cleavable vs. Non-Cleavable Linkers in Antibody-Drug Conjugates
- Innovative Linker Technology for Antibody Drug Conjugates (ADCs)
- FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer
- ADC Drugs to be Launched In 2020
- Anti-Cancer ADC Drugs: 3 Design Elements, 8 Approved ADCs, Multiple Clinical Trials
- PEGs Conjugate a Versatile Approach of Antibody Drug
- Overviews of the Antibody-drug conjugates (ADCs)
- ADCs Against Cancer: Clinical Landscape and Challenges
- History and Development of Antibody Drug Conjugates (ADCs)
- ADCs for Clinical Research in the Global Market